5-α reductase inhibitors and prostate cancer prevention: where do we turn now?

Loading...
Thumbnail Image

Date

2011-09-15

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

1003
views
517
downloads

Citation Stats

Abstract

With the lifetime risk of being diagnosed with prostate cancer so great, an effective chemopreventive agent could have a profound impact on the lives of men. Despite decades of searching for such an agent, physicians still do not have an approved drug to offer their patients. In this article, we outline current strategies for preventing prostate cancer in general, with a focus on the 5-α-reductase inhibitors (5-ARIs) finasteride and dutasteride. We discuss the two landmark randomized, controlled trials of finasteride and dutasteride, highlighting the controversies stemming from the results, and address the issue of 5-ARI use, including reasons why providers may be hesitant to use these agents for chemoprevention. We further discuss the recent US Food and Drug Administration ruling against the proposed new indication for dutasteride and the change to the labeling of finasteride, both of which were intended to permit physicians to use the drugs for chemoprevention. Finally, we discuss future directions for 5-ARI research.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.1186/1741-7015-9-105

Publication Info

Hamilton, Robert J, and Stephen J Freedland (2011). 5-α reductase inhibitors and prostate cancer prevention: where do we turn now?. BMC Med, 9. p. 105. 10.1186/1741-7015-9-105 Retrieved from https://hdl.handle.net/10161/8912.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.